source
- Definium Therapeutics reports positive Phase 3 results for oral LSD anxiety drug DT120Definium Therapeutics announced Monday that its experimental oral LSD formulation, DT120, achieved positive outcomes in a Phase 3 trial targeting an anxiety disorder. The trial, the company's thir…
- FDA signals openness to innovative approaches for psychedelic drug developmentFDA officials said the agency is open to novel, innovative approaches to the clinical development of psychedelic drugs, citing the worsening mental health crisis in the United States. The agency’s…